If high Lp(a) levels are associated with an increased risk for recurrent ASCVD events in adults with CKD, this may represent an opportunity for ASCVD risk reduction in this high-risk population through novel Lp(a)-lowering therapies.6 This evidence concerns the gene LPA and atherosclerosis.